Candriam SCA
DOVA

Candriam SCA’s Dova Pharmaceuticals, Inc. Common Stock DOVA Stock Holding History

Candriam SCA’s Portfolio DOVA Stock Details DOVA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q2 		– Sell
-233,200
Closed -$2.07M – 854
2019
Q1 		$2.07M Hold
233,200
– – 0.03% 490
2018
Q4 		$1.77M Hold
233,200
– – 0.03% 485
2018
Q3 		$4.89M Buy
233,200
+114,000
+96% +$2.71M 0.07% 321
2018
Q2 		$3.57M Buy
119,200
+39,200
+49% +$1.07M 0.06% 362
2018
Q1 		$2.17M Buy
+80,000
New +$2.39M 0.04% 465

Other funds holding DOVA

Perceptive Advisors
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Sanders Morris Harris
Sanders Morris Harris Houston, Texas $755M AUM 11.28% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
GW&K Investment Management
GW&K Investment Management Boston, Massachusetts $12.8B AUM 48.82% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return

Candriam SCA's DOVA Position: Q2 2019 in Review

Candriam SCA sold out of Dova Pharmaceuticals, Inc. Common Stock (DOVA) in Q2 2019, closing a stake of 233,200 shares — an estimated $2.07M sold.

Candriam SCA first reported a position in DOVA in Q1 2018 and held it in 5 quarters. The position peaked at $4.89M in Q3 2018. 66 funds tracked by Wall St. Rank hold DOVA as of Q2 2019.

  • Candriam SCA reported no remaining Dova Pharmaceuticals, Inc. Common Stock position as of Q2 2019 after selling out during the quarter.
  • Candriam SCA sold 233,200 Dova Pharmaceuticals, Inc. Common Stock shares in Q2 2019, an estimated $2.07M.
  • Candriam SCA first reported a position in Dova Pharmaceuticals, Inc. Common Stock in Q1 2018 and held it in 5 quarters.
  • Candriam SCA's Dova Pharmaceuticals, Inc. Common Stock position peaked at $4.89M in Q3 2018.
  • 66 funds tracked by Wall St. Rank held Dova Pharmaceuticals, Inc. Common Stock as of Q2 2019.

Based on Candriam SCA's 13F filing for Q2 2019, filed 1 Aug 2019.